11 Oct

Analysts Raise Target Prices on ABT ahead of Q3 Earnings

WRITTEN BY Sarah Collins

Analysts’ recommendations for ABT

Abbott Laboratories (ABT) is slated to announce its Q3 earnings results on October 17. Let’s look at Wall Street analysts’ recommendations for ABT stock ahead of its earnings release.

As of October 11, as per a recent Reuters survey, which included 19 investment research firms covering ABT stock, 42% of analysts have a “strong buy” recommendation on ABT stock, while 37% have a “buy” rating for the stock. The remaining four analysts gave Abbott Laboratories a “hold” recommendation. The chart below shows a 12-month recommendation summary for ABT stock over the last few months.

Analysts Raise Target Prices on ABT ahead of Q3 Earnings

Target price

On October 11, Abbott Laboratories had a consensus 12-month target price of $75.38, implying a 12-month investment return potential of 9.4%. That return is based on the stock’s closing price of $68.92 on October 10.

Peers Boston Scientific (BSX), Thermo Fisher Scientific (TMO), and Medtronic (MDT) had average analyst target prices of $40.32, $259.47, and $103.15, respectively. These price targets imply 12-month returns of 11.7%, 12.5%, and 8.5%, respectively.

Revisions and updates

On October 10, Morgan Stanley increased its target price on Abbott Laboratories from $70 to $80. On October 8, J.P. Morgan raised its target price on ABT stock from $77 to $81. On October 5, Cowen and Company also raised its target price on Abbott Laboratories from $72 to $86. Last month, on September 28, Wells Fargo had also increased its target price on ABT stock from $80 to $83.

Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!

Latest articles

On October 17, Cannabis 2.0 legalized edibles, beverages, and concentrates in Canada. As the country waits for the benefits, is Cannabis 3.0 next?

Prohibition Partners expects that by 2024, the legal cannabis market could reach $103.9 billion and the medical cannabis market could reach $62.6 billion.

The cannabis sector was trading in the red today. MKM Partners lowered its revenue estimates for Canopy Growth (CGC) (WEED) and Aurora Cannabis (ACB).

Ford plans to unveil its crossover SUV, the Mach-E, on November 17. Ford committed $11.5 billion toward the electrification of its fleet through 2022.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it's illegal in Kansas. Even having a small amount is considered a crime.